

## From Awareness to Action: Recommendations for HIV-Positive Pregnant Women

\*Emmanuel Ifeanyi Obeagu<sup>1</sup> and Getrude Uzoma Obeagu<sup>2</sup>

<sup>1</sup>Department of Medical Laboratory Science, Kampala International University, Uganda

<sup>2</sup>School of Nursing Science, Kampala International University, Uganda.

\*Corresponding authour: Emmanuel Ifeanyi Obeagu, [Department of Medical Laboratory Science, Kampala International University, Uganda, emmanuelobeagu@yahoo.com, ORCID: 0000-0002-4538-0161](#)

### Abstract

Preventing mother-to-child transmission (PMTCT) of human immunodeficiency virus (HIV) is a critical component of maternal and child health programs worldwide. HIV-positive pregnant women face unique challenges and considerations in managing their health and preventing vertical transmission of HIV to their infants. This review provides recommendations for HIV-positive pregnant women, focusing on key strategies to promote optimal maternal and infant outcomes. Topics covered include the importance of early HIV diagnosis, initiation of antiretroviral therapy (ART), adherence to treatment regimens, infant feeding options, and access to healthcare services. By translating awareness into action, HIV-positive pregnant women can take proactive steps to protect their own health and prevent HIV transmission to their infants.

**Keywords:** *HIV, pregnancy, prevention of mother-to-child transmission, antiretroviral therapy, adherence, infant feeding, healthcare access*

### Introduction

Preventing mother-to-child transmission (PMTCT) of human immunodeficiency virus (HIV) is a critical component of global efforts to combat the HIV/AIDS epidemic and improve maternal and child health outcomes. HIV-positive pregnant women face unique challenges and considerations in managing their health and preventing vertical transmission of HIV to their infants. Despite significant progress in PMTCT efforts, gaps in awareness, access to care, and adherence to treatment regimens persist, particularly in resource-limited settings where the burden of HIV infection is highest. Consequently, there is a pressing need to provide comprehensive support and

**Citation:** Obeagu EI, Onuoha EC. From Awareness to Action: Recommendations for HIV-Positive Pregnant Women. *Elite Journal of Public Health*, 2024; 2 (4): 75-93

guidance to HIV-positive pregnant women, empowering them to take proactive steps to protect their own health and prevent HIV transmission to their infants. The journey from awareness to action for HIV-positive pregnant women begins with early HIV diagnosis and initiation of antiretroviral therapy (ART). Early diagnosis allows pregnant women to access timely care and treatment interventions, reducing the risk of vertical transmission and improving maternal health outcomes. However, achieving timely diagnosis and linkage to care remains a challenge in many settings due to barriers such as stigma, discrimination, and limited access to healthcare services. Therefore, efforts to promote routine HIV testing as part of prenatal care and provide support for women who test positive are essential for enabling early diagnosis and ART initiation.<sup>1-40</sup>

Adherence to ART throughout pregnancy, childbirth, and the postpartum period is crucial for achieving viral suppression and reducing the risk of vertical transmission. HIV-positive pregnant women should be supported in maintaining optimal adherence to their treatment regimens through counseling, peer support groups, and medication reminders. Additionally, comprehensive counseling on infant feeding options is essential for helping women make informed decisions that minimize the risk of vertical transmission while promoting infant health and well-being. Access to healthcare services, including prenatal care, HIV treatment, and PMTCT services, is fundamental for ensuring optimal maternal and infant outcomes. However, barriers such as transportation, cost, and stigma often hinder women's access to care, highlighting the need for strategies to improve healthcare access and promote engagement in care among HIV-positive pregnant women.<sup>41-60</sup>

### **Importance of Early HIV Diagnosis**

Early HIV diagnosis is paramount in the context of preventing mother-to-child transmission (PMTCT) of the virus. For pregnant women, early detection of HIV infection allows for timely initiation of antiretroviral therapy (ART), which is crucial for suppressing viral replication and reducing the risk of vertical transmission to the unborn child. HIV testing should be integrated into routine prenatal care services to ensure that all pregnant women have access to testing and receive their results promptly. Early diagnosis enables healthcare providers to offer appropriate counseling, support, and medical interventions to pregnant women living with HIV, improving their health outcomes and reducing the likelihood of transmission to their infants. Furthermore, early HIV diagnosis allows pregnant women to make informed decisions about their own health and the health of their infants. Knowledge of one's HIV status empowers women to take proactive steps to protect themselves and their babies, such as adhering to ART regimens, practicing safer sex, and making informed choices about infant feeding options. Additionally, early diagnosis provides an opportunity for pregnant women to access supportive services, including counseling, peer support groups, and psychosocial support, which can help alleviate the emotional and psychological burdens associated with living with HIV during pregnancy. In the context of PMTCT, early diagnosis is critical for maximizing the effectiveness of interventions aimed at reducing the risk of vertical transmission. Studies have shown that initiating ART early during pregnancy significantly reduces the risk of vertical transmission compared to delayed initiation or no treatment. Therefore, identifying HIV-positive pregnant women early in pregnancy allows for timely initiation of ART, increasing the likelihood of achieving viral suppression and reducing the

**Citation:** Obeagu EI, Onuoha EC. From Awareness to Action: Recommendations for HIV-Positive Pregnant Women. *Elite Journal of Public Health*, 2024; 2 (4): 75-93

risk of transmission to the infant. By prioritizing early HIV diagnosis as part of comprehensive prenatal care services, healthcare systems can play a pivotal role in improving maternal and child health outcomes and advancing efforts to eliminate pediatric HIV infections.<sup>61-100</sup>

### **Initiation and Adherence to Antiretroviral Therapy (ART)**

Initiation and adherence to antiretroviral therapy (ART) are critical components of preventing mother-to-child transmission (PMTCT) of human immunodeficiency virus (HIV). For HIV-positive pregnant women, ART plays a crucial role in reducing maternal viral load, preventing vertical transmission to the infant, and improving maternal health outcomes. Initiating ART promptly after diagnosis and maintaining optimal adherence throughout pregnancy, childbirth, and the postpartum period are essential for maximizing the effectiveness of PMTCT interventions and achieving the goal of eliminating pediatric HIV infections. Initiating ART during pregnancy suppresses viral replication, reducing the maternal viral load and the risk of vertical transmission to the unborn child. Studies have shown that early initiation of ART significantly reduces the risk of vertical transmission compared to delayed initiation or no treatment. Therefore, HIV-positive pregnant women should be encouraged to start ART as soon as possible after diagnosis, ideally during the first trimester of pregnancy. Prompt initiation of ART allows for sufficient time to achieve viral suppression before childbirth, minimizing the risk of transmission during labor and delivery.

Adherence to ART regimens is crucial for maintaining viral suppression and reducing the risk of vertical transmission throughout pregnancy and breastfeeding. HIV-positive pregnant women should be supported in maintaining optimal adherence to their treatment regimens through counseling, education, and support services. Adherence support interventions, such as medication reminders, pill organizers, and peer support groups, can help women overcome barriers to adherence and maintain consistent use of ART. Additionally, healthcare providers should regularly monitor adherence and provide individualized support to address any challenges or concerns that may arise. Adherence to ART is not only beneficial for preventing vertical transmission but also for improving maternal health outcomes. Effective ART reduces the risk of HIV-related complications and opportunistic infections, allowing pregnant women to maintain their health and well-being throughout pregnancy and beyond. Furthermore, achieving viral suppression through ART enables HIV-positive women to have healthy pregnancies, reduce the risk of HIV transmission to their sexual partners, and lead fulfilling lives as mothers and caregivers.<sup>101-140</sup>

### **Infant Feeding Options**

Infant feeding options are a crucial consideration for HIV-positive mothers, as they play a significant role in preventing mother-to-child transmission (PMTCT) of human immunodeficiency virus (HIV) while promoting optimal infant health and nutrition. HIV-positive mothers face complex decisions regarding infant feeding, balancing the benefits of breastfeeding with the risk of HIV transmission through breast milk. Exclusive formula feeding involves feeding the infant with commercially available infant formula without any breastfeeding. This option eliminates the risk of HIV transmission through breast milk and is recommended in settings where safe and

**Citation:** Obeagu EI, Onuoha EC. From Awareness to Action: Recommendations for HIV-Positive Pregnant Women. *Elite Journal of Public Health*, 2024; 2 (4): 75-93

affordable alternatives to breastfeeding are available. Exclusive formula feeding provides complete nutrition to the infant and reduces the risk of other infections, such as diarrheal diseases and respiratory infections, associated with breastfeeding in resource-limited settings. Exclusive breastfeeding with maternal antiretroviral therapy (ART) involves breastfeeding while the mother is receiving ART to suppress viral replication and reduce the risk of HIV transmission through breast milk. Studies have shown that when the mother adheres to ART and achieves viral suppression, the risk of vertical transmission through breastfeeding is significantly reduced. This option allows HIV-positive mothers to provide the benefits of breastfeeding, including essential nutrients, antibodies, and bonding, while minimizing the risk of HIV transmission to the infant.<sup>141-170</sup>

Mixed feeding involves combining breastfeeding with other foods or fluids, such as water, infant formula, or solid foods. This feeding practice increases the risk of HIV transmission compared to exclusive breastfeeding or exclusive formula feeding and is not recommended for HIV-positive mothers. Mixed feeding can lead to nipple trauma, increased viral exposure through breast milk, and interference with the protective factors present in breast milk, increasing the risk of vertical transmission. Early introduction of complementary foods involves introducing solid foods to the infant before the age of six months, in addition to breastfeeding or formula feeding. This practice is not recommended for HIV-positive mothers, as it may increase the risk of HIV transmission due to the infant's immature immune system and potential damage to the gastrointestinal tract. Delaying the introduction of complementary foods until the age of six months, in line with World Health Organization (WHO) guidelines, reduces the risk of HIV transmission and supports optimal infant growth and development.<sup>171-180</sup>

### **Access to Healthcare Services**

Access to healthcare services is a fundamental component of preventing mother-to-child transmission (PMTCT) of human immunodeficiency virus (HIV) and ensuring optimal maternal and infant health outcomes. HIV-positive pregnant women require comprehensive care and support throughout pregnancy, childbirth, and the postpartum period to access essential services, including antenatal care, HIV testing, antiretroviral therapy (ART), and PMTCT interventions. However, barriers to healthcare access persist, particularly in resource-limited settings, hindering the ability of HIV-positive pregnant women to receive timely and quality care. Barriers to healthcare access for HIV-positive pregnant women include geographical, financial, social, and cultural factors that limit their ability to access healthcare services. Geographical barriers, such as long distances to healthcare facilities and lack of transportation, pose challenges for pregnant women in rural and underserved areas, where healthcare services may be scarce or unavailable. Financial barriers, including out-of-pocket costs for medical care, medications, and transportation, can prevent women from seeking prenatal care, HIV testing, and ART services, particularly in low-income communities.<sup>181-190</sup>

Social and cultural factors, such as stigma, discrimination, and gender inequality, also contribute to barriers to healthcare access for HIV-positive pregnant women. Fear of HIV-related stigma and discrimination may deter women from seeking HIV testing and treatment services, disclosing their

**Citation:** Obeagu EI, Onuoha EC. From Awareness to Action: Recommendations for HIV-Positive Pregnant Women. *Elite Journal of Public Health*, 2024; 2 (4): 75-93

HIV status, or adhering to PMTCT interventions. Gender-based inequalities, including lack of decision-making power and autonomy, may further hinder women's ability to access healthcare services and make informed choices about their health and the health of their infants. To address these barriers and improve access to healthcare services for HIV-positive pregnant women, comprehensive strategies are needed to strengthen health systems, reduce financial barriers, address social and cultural determinants of health, and empower women to seek care and support. Health system strengthening efforts should focus on expanding access to HIV testing and treatment services, integrating PMTCT services into routine maternal and child health programs, and improving the availability and quality of care in underserved areas. Financial barriers can be addressed through innovative financing mechanisms, such as health insurance schemes, fee waivers, and subsidies for essential healthcare services and medications. Additionally, community-based interventions, including peer support groups, community health workers, and mobile health (mHealth) initiatives, can help overcome social and cultural barriers by providing tailored support and education to HIV-positive pregnant women and their families.<sup>191-199</sup>

## Conclusion

Access to healthcare services is a cornerstone of preventing mother-to-child transmission (PMTCT) of human immunodeficiency virus (HIV) and ensuring the health and well-being of HIV-positive pregnant women and their infants. Despite significant progress in PMTCT efforts, barriers to healthcare access persist, particularly in resource-limited settings, hindering the ability of women to receive timely and quality care. Financial barriers can be overcome through innovative financing mechanisms, such as health insurance schemes, fee waivers, and subsidies for essential healthcare services and medications. Community-based interventions, including peer support groups, community health workers, and mobile health initiatives, play a crucial role in overcoming social and cultural barriers by providing tailored support and education to HIV-positive pregnant women and their families.

## References

1. Mann Z, Sengar M, Verma YK, Rajalingam R, Raghav PK. Hematopoietic stem cell factors: their functional role in self-renewal and clinical aspects. *Frontiers in Cell and Developmental Biology*. 2022; 10:664261.
2. Sezaki M, Hayashi Y, Wang Y, Johansson A, Umemoto T, Takizawa H. Immunomodulation of hematopoietic stem and progenitor cells in inflammation. *Frontiers in immunology*. 2020; 11:585367.
3. Okeke C, Silas U, Okeke C, Chikwendu C. Current trends on hemopoietic stem cells. *Current Stem Cell Research & Therapy*. 2021;16(2):199-208.
4. Lee J, Yoon SR, Choi I, Jung H. Causes and mechanisms of hematopoietic stem cell aging. *International Journal of Molecular Sciences*. 2019;20(6):1272.
5. Govindarajah V, Reynaud D. Tuning of the hematopoietic stem cell compartment in its inflammatory environment. *Current stem cell reports*. 2018; 4:189-200.

**Citation:** Obeagu EI, Onuoha EC. From Awareness to Action: Recommendations for HIV-Positive Pregnant Women. *Elite Journal of Public Health*, 2024; 2 (4): 75-93



6. Abunimye DA, Okafor IM, Okorowo H, Obeagu EI. The role of GATA family transcriptional factors in haematological malignancies: A review. *Medicine*. 2024;103(12): e37487.
7. Obeagu EI, Okoroiwu IL, Azuonwu O. An update on hypoxic regulation of iron homeostasis and bone marrow environment. *Int. J. Curr. Res. Med. Sci.* 2018;4(10):42-8.
8. Obeagu EI, Okoroiwu IL, Obeagu G. Molecular mechanism and systemic response of erythropoietin: A Review. *Int. J. Adv. Res. Biol. Sci.* 2015;2(7):58-62.
9. Ifeanyi OE. Acute Leukaemia: A Sudden Killer to Human Beings. *EC Emergency Medicine and Critical Care*. 2020;4(6):154-67.
10. Obeagu EI, Okwuanaso CB, Edoho SH, Obeagu GU. Under-nutrition among HIV-exposed Uninfected Children: A Review of African Perspective. *Madonna University journal of Medicine and Health Sciences*. 2022;2(3):120-127.
11. Obeagu EI. A Review of Challenges and Coping Strategies Faced by HIV/AIDS Discordant Couples. *Madonna University journal of Medicine and Health Sciences*. 2023 ;3(1):7-12.  
<https://madonnauniversity.edu.ng/journals/index.php/medicine/article/view/91>.
12. Obeagu EI, Obeagu GU. An update on premalignant cervical lesions and cervical cancer screening services among HIV positive women. *J Pub Health Nutri.* 2023; 6 (2). 2023; 141:1-2. [links/63e538ed64252375639dd0df/An-update-on-premalignant-cervical-lesions-and-cervical-cancer-screening-services-among-HIV-positive-women.pdf](https://doi.org/10.22192/ijcrms.2017.03.01.004).
13. Ezeoru VC, Enweani IB, Ochiabuto O, Nwachukwu AC, Ogbonna US, Obeagu EI. Prevalence of Malaria with Anaemia and HIV status in women of reproductive age in Onitsha, Nigeria. *Journal of Pharmaceutical Research International*. 2021;33(4):10-19.
14. Omo-Emmanuel UK, Chinedum OK, Obeagu EI. Evaluation of laboratory logistics management information system in HIV/AIDS comprehensive health facilities in Bayelsa State, Nigeria. *Int J Curr Res Med Sci.* 2017;3(1): 21-38.DOI: [10.22192/ijcrms.2017.03.01.004](https://doi.org/10.22192/ijcrms.2017.03.01.004)
15. Obeagu EI, Obeagu GU, Musiimenta E, Bot YS, Hassan AO. Factors contributing to low utilization of HIV counseling and testing services. *Int. J. Curr. Res. Med. Sci.* 2023;9(2): 1-5.DOI: [10.22192/ijcrms.2023.09.02.001](https://doi.org/10.22192/ijcrms.2023.09.02.001)
16. Obeagu EI, Obeagu GU. An update on survival of people living with HIV in Nigeria. *J Pub Health Nutri.* 2022; 5 (6). 2022;129. [links/645b4bfcf3512f1cc5885784/An-update-on-survival-of-people-living-with-HIV-in-Nigeria.pdf](https://doi.org/10.22192/ijcrms.2023.09.02.001).
17. Offie DC, Obeagu EI, Akueshi C, Njab JE, Ekanem EE, Dike PN, Oguh DN. Facilitators and barriers to retention in HIV care among HIV infected MSM attending Community Health Center Yaba, Lagos Nigeria. *Journal of Pharmaceutical Research International*. 2021;33(52B):10-19.
18. Obeagu EI, Ogbonna US, Nwachukwu AC, Ochiabuto O, Enweani IB, Ezeoru VC. Prevalence of Malaria with Anaemia and HIV status in women of reproductive age in Onitsha, Nigeria. *Journal of Pharmaceutical Research International*. 2021;33(4):10-19.
19. Odo M, Ochei KC, Obeagu EI, Barinaadaa A, Eteng UE, Ikpeme M, Bassey JO, Paul AO. TB Infection Control in TB/HIV Settings in Cross River State, Nigeria: Policy Vs Practice. *Journal of Pharmaceutical Research International*. 2020;32(22):101-119.

20. Obeagu EI, Eze VU, Alaebob EA, Ochei KC. Determination of haematocrit level and iron profile study among persons living with HIV in Umuahia, Abia State, Nigeria. J BioInnovation. 2016; 5:464-471. [links/592bb4990f7e9b9979a975cf/DETERMINATION-OF-HAEMATOCRIT-LEVEL-AND-IRON-PROFILE-STUDY-AMONG-PERSONS-LIVING-WITH-HIV-IN-UMUAHIA-ABIA-STATE-NIGERIA.pdf](https://www.academia.edu/download/38320140/Obeagu_Emanuel_Ifeanyi_and_Obeagu_Getrude_Uzoma2.EMMA1.pdf).
21. Ifeanyi OE, Obeagu GU. The values of prothrombin time among HIV positive patients in FMC owerri. International Journal of Current Microbiology and Applied Sciences. 2015;4(4):911-916. [https://www.academia.edu/download/38320140/Obeagu\\_Emanuel\\_Ifeanyi\\_and\\_Obeagu\\_Getrude\\_Uzoma2.EMMA1.pdf](https://www.academia.edu/download/38320140/Obeagu_Emanuel_Ifeanyi_and_Obeagu_Getrude_Uzoma2.EMMA1.pdf).
22. Izuchukwu IF, Ozims SJ, Agu GC, Obeagu EI, Onu I, Amah H, Nwosu DC, Nwanjo HU, Edward A, Arunsi MO. Knowledge of preventive measures and management of HIV/AIDS victims among parents in Umuna Orlu community of Imo state Nigeria. Int. J. Adv. Res. Biol. Sci. 2016;3(10): 55-65.DOI; [10.22192/ijarbs.2016.03.10.009](https://doi.org/10.22192/ijarbs.2016.03.10.009)
23. Chinedu K, Takim AE, Obeagu EI, Chinazor UD, Eloghosa O, Ojong OE, Odunze U. HIV and TB co-infection among patients who used Directly Observed Treatment Short-course centres in Yenagoa, Nigeria. IOSR J Pharm Biol Sci. 2017;12(4):70-75. [links/5988ab6d0f7e9b6c8539f73d/HIV-and-TB-co-infection-among-patients-who-used-Directly-Observed-Treatment-Short-course-centres-in-Yenagoa-Nigeria.pdf](https://www.academia.edu/download/38320140/Obeagu_Emanuel_Ifeanyi_and_Obeagu_Getrude_Uzoma2.EMMA1.pdf)
24. Oloro OH, Oke TO, Obeagu EI. Evaluation of Coagulation Profile Patients with Pulmonary Tuberculosis and Human Immunodeficiency Virus in Owo, Ondo State, Nigeria. Madonna University journal of Medicine and Health Sciences. 2022;2(3):110-119.
25. Nwosu DC, Obeagu EI, Nkwocha BC, Nwanna CA, Nwanjo HU, Amadike JN, Elendu HN, Ofoedeme CN, Ozims SJ, Nwankpa P. Change in Lipid Peroxidation Marker (MDA) and Non enzymatic Antioxidants (VIT C & E) in HIV Seropositive Children in an Urban Community of Abia State. Nigeria. J. Bio. Innov. 2016;5(1):24-30. [links/5ae735e9a6fdcc5b33eb8d6a/CHANGE-IN-LIPID-PEROXIDATION-MARKER-MDAAND-NON-ENZYMATIC-ANTIOXIDANTS-VIT-C-E-IN-HIV-SEROPOSITIVE-CHILDREN-IN-AN-URBAN-COMMUNITY-OF-ABIA-STATE-NIGERIA.pdf](https://www.academia.edu/download/38320140/Obeagu_Emanuel_Ifeanyi_and_Obeagu_Getrude_Uzoma2.EMMA1.pdf).
26. Igwe CM, Obeagu IE, Ogbuabor OA. Clinical characteristics of people living with HIV/AIDS on ART in 2014 at tertiary health institutions in Enugu, Nigeria. J Pub Health Nutri. 2022; 5 (6). 2022;130. [links/645a166f5762c95ac3817d32/Clinical-characteristics-of-people-living-with-HIV-AIDS-on-ART-in-2014-at-tertiary-health-institutions-in-Enugu.pdf](https://www.academia.edu/download/38320140/Obeagu_Emanuel_Ifeanyi_and_Obeagu_Getrude_Uzoma2.EMMA1.pdf).
27. Ifeanyi OE, Obeagu GU, Ijeoma FO, Chioma UI. The values of activated partial thromboplastin time (APTT) among HIV positive patients in FMC Owerri. Int J Curr Res Aca Rev. 2015; 3:139-144. [https://www.academia.edu/download/38320159/Obeagu\\_Emanuel\\_Ifeanyi3\\_et\\_al.IJC\\_RAR.pdf](https://www.academia.edu/download/38320159/Obeagu_Emanuel_Ifeanyi3_et_al.IJC_RAR.pdf).
28. Obiomah CF, Obeagu EI, Ochei KC, Swem CA, Amachukwu BO. Hematological indices o HIV seropositive subjects in Nnamdi Azikiwe University teaching hospital (NAUTH), Nnewi. Ann Clin Lab Res. 2018;6(1):1-4.

[links/5aa2bb17a6fdccd544b7526e/Haematological-Indices-of-HIV-Seropositive-Subjects-at-Nnamdi-Azikiwe.pdf](#)

29. Omo-Emmanuel UK, Ochei KC, Osuala EO, Obeagu EI, Onwuasoanya UF. Impact of prevention of mother to child transmission (PMTCT) of HIV on positivity rate in Kafanchan, Nigeria. *Int. J. Curr. Res. Med. Sci.* 2017;3(2): 28-34.DOI: [10.22192/ijcrms.2017.03.02.005](#)
30. Aizaz M, Abbas FA, Abbas A, Tabassum S, Obeagu EI. Alarming rise in HIV cases in Pakistan: Challenges and future recommendations at hand. *Health Science Reports.* 2023;6(8):e1450.
31. Obeagu EI, Amekpor F, Scott GY. An update of human immunodeficiency virus infection: Bleeding disorders. *J Pub Health Nutri.* 2023; 6 (1). 2023;139. [links/645b4a6c2edb8e5f094d9bd9/An-update-of-human-immunodeficiency-virus-infection-Bleeding.pdf](#).
32. Obeagu EI, Scott GY, Amekpor F, Ofodile AC, Edoho SH, Ahamefula C. Prevention of New Cases of Human Immunodeficiency Virus: Pragmatic Approaches of Saving Life in Developing Countries. *Madonna University journal of Medicine and Health Sciences.* 2022;2(3):128-134. <https://madonnauniversity.edu.ng/journals/index.php/medicine/article/view/86>.
33. Walter O, Anaabo QB, Obeagu EI, Okoroiwu IL. Evaluation of Activated Partial Thromboplastin Time and Prothrombin Time in HIV and TB Patients in Owerri Metropolis. *Journal of Pharmaceutical Research International.* 2022:29-34.
34. Odo M, Ochei KC, Obeagu EI, Barinaadaa A, Eteng EU, Ikpeme M, Bassey JO, Paul AO. Cascade variabilities in TB case finding among people living with HIV and the use of IPT: assessment in three levels of care in cross River State, Nigeria. *Journal of Pharmaceutical Research International.* 2020;32(24):9-18.
35. Jakheng SP, Obeagu EI. Seroprevalence of human immunodeficiency virus based on demographic and risk factors among pregnant women attending clinics in Zaria Metropolis, Nigeria. *J Pub Health Nutri.* 2022; 5 (8). 2022;137. [links/6317a6b1acd814437f0ad268/Seroprevalence-of-human-immunodeficiency-virus-based-on-demographic-and-risk-factors-among-pregnant-women-attending-clinics-in-Zaria-Metropolis-Nigeria.pdf](#).
36. Obeagu EI, Obeagu GU. A Review of knowledge, attitudes and socio-demographic factors associated with non-adherence to antiretroviral therapy among people living with HIV/AIDS. *Int. J. Adv. Res. Biol. Sci.* 2023;10(9):135-142.DOI: [10.22192/ijarbs.2023.10.09.015](#) [links/6516faa61e2386049de5e828/A-Review-of-knowledge-attitudes-and-socio-demographic-factors-associated-with-non-adherence-to-antiretroviral-therapy-among-people-living-with-HIV-AIDS.pdf](#)
37. Obeagu EI, Onuoha EC. Tuberculosis among HIV Patients: A review of Prevalence and Associated Factors. *Int. J. Adv. Res. Biol. Sci.* 2023;10(9):128-134.DOI: [10.22192/ijarbs.2023.10.09.014](#) [links/6516f938b0df2f20a2f8b0e0/Tuberculosis-among-HIV-Patients-A-review-of-Prevalence-and-Associated-Factors.pdf](#).
38. Obeagu EI, Ibeh NC, Nwobodo HA, Ochei KC, Iwegbulam CP. Haematological indices of malaria patients coinfectd with HIV in Umuahia. *Int. J. Curr. Res. Med. Sci.* 2017;3(5):100-104.DOI: [10.22192/ijcrms.2017.03.05.014](#)

**Citation:** Obeagu EI, Onuoha EC. From Awareness to Action: Recommendations for HIV-Positive Pregnant Women. *Elite Journal of Public Health*, 2024; 2 (4): 75-93



[https://www.academia.edu/download/54317126/Haematological indices of malaria patients coinfected with HIV.pdf](https://www.academia.edu/download/54317126/Haematological_indices_of_malaria_patients_coinfected_with_HIV.pdf)

39. Jakheng SP, Obeagu EI, Abdullahi IO, Jakheng EW, Chukwueze CM, Eze GC, Essien UC, Madekwe CC, Madekwe CC, Vidya S, Kumar S. Distribution Rate of Chlamydial Infection According to Demographic Factors among Pregnant Women Attending Clinics in Zaria Metropolis, Kaduna State, Nigeria. South Asian Journal of Research in Microbiology. 2022;13(2):26-31.
40. Okorie HM, Obeagu Emmanuel I, Okpoli Henry CH, Chukwu Stella N. Comparative study of enzyme linked immunosorbent assay (Elisa) and rapid test screening methods on HIV, Hbsag, Hcv and Syphilis among voluntary donors in. Owerri, Nigeria. J Clin Commun Med. 2020;2(3):180-183.DOI: **DOI:** [10.32474/JCCM.2020.02.000137](https://doi.org/10.32474/JCCM.2020.02.000137)  
[links/5f344530458515b7291bd95f/Comparative-Study-of-Enzyme-Linked-Immunosorbent-Assay-ELISA-and-Rapid-Test-Screening-Methods-on-HIV-HBsAg-HCV-and-Syphilis-among-Voluntary-Donors-in-Owerri-Nigeria.pdf](https://doi.org/10.32474/JCCM.2020.02.000137/links/5f344530458515b7291bd95f/Comparative-Study-of-Enzyme-Linked-Immunosorbent-Assay-ELISA-and-Rapid-Test-Screening-Methods-on-HIV-HBsAg-HCV-and-Syphilis-among-Voluntary-Donors-in-Owerri-Nigeria.pdf).
41. Ezugwu UM, Onyenekwe CC, Ukibe NR, Ahaneku JE, Onah CE, Obeagu EI, Emeje PI, Awalu JC, Igbokwe GE. Use of ATP, GTP, ADP and AMP as an Index of Energy Utilization and Storage in HIV Infected Individuals at NAUTH, Nigeria: A Longitudinal, Prospective, Case-Controlled Study. Journal of Pharmaceutical Research International. 2021;33(47A):78-84.
42. Emannuel G, Martin O, Peter OS, Obeagu EI, Daniel K. Factors Influencing Early Neonatal Adverse Outcomes among Women with HIV with Post Dated Pregnancies Delivering at Kampala International University Teaching Hospital, Uganda. Asian Journal of Pregnancy and Childbirth. 2023 Jul 29;6(1):203-211.  
<http://research.sdpublishers.net/id/eprint/2819/>.
43. Igwe MC, Obeagu EI, Ogbuabor AO, Eze GC, Ikpenwa JN, Eze-Sтивен PE. Socio-Demographic Variables of People Living with HIV/AIDS Initiated on ART in 2014 at Tertiary Health Institution in Enugu State. Asian Journal of Research in Infectious Diseases. 2022;10(4):1-7.
44. Vincent CC, Obeagu EI, Agu IS, Ukeagu NC, Onyekachi-Chigbu AC. Adherence to Antiretroviral Therapy among HIV/AIDS in Federal Medical Centre, Owerri. Journal of Pharmaceutical Research International. 2021;33(57A):360-368.
45. Igwe MC, Obeagu EI, Ogbuabor AO. Analysis of the Factors and Predictors of Adherence to Healthcare of People Living With Hiv/Aids In Tertiary Health Institutions In Enugu State. Madonna University Journal of Medicine and Health Sciences. 2022;2(3):42-57.  
<https://madonnauniversity.edu.ng/journals/index.php/medicine/article/view/75>.
46. Madekwe CC, Madekwe CC, Obeagu EI. Inequality of monitoring in Human Immunodeficiency Virus, Tuberculosis and Malaria: A Review. Madonna University journal of Medicine and Health Sciences. 2022;2(3):6-15.  
<https://madonnauniversity.edu.ng/journals/index.php/medicine/article/view/69>
47. Echendu GE, Vincent CC, Ibebuikwe J, Asodike M, Naze N, Chinedu EP, Ohale B, Obeagu EI. WEIGHTS OF INFANTS BORN TO HIV INFECTED MOTHERS: A PROSPECTIVE COHORT STUDY IN FEDERAL MEDICAL CENTRE, OWERRI, IMO STATE. European Journal of Pharmaceutical and Medical Research, 2023; 10(8): 564-568

**Citation:** Obeagu EI, Onuoha EC. From Awareness to Action: Recommendations for HIV-Positive Pregnant Women. Elite Journal of Public Health, 2024; 2 (4): 75-93

48. Nwosu DC, Nwanjo HU, Okolie NJ, Ikek K, Ajero CM, Dike J, Ojiegbe GC, Oze GO, Obeagu EI, Nnatunanya I, Azuonwu O. BIOCHEMICAL ALTERATIONS IN ADULT HIV PATIENTS ON ANTIRETROVIRAL THERAPY. World Journal of Pharmacy and Pharmaceutical Sciences, 2015; 4(3): 153-160.  
[links/5a4fd0500f7e9bbc10526b38/BIOCHEMICAL-ALTERATIONS-IN-ADULT-HIV-PATIENTS-ON-ANTIRETROVIRAL-THERAPY.pdf.](#)
49. Obeagu EI, Obeagu GU. Effect of CD4 Counts on Coagulation Parameters among HIV Positive Patients in Federal Medical Centre, Owerri, Nigeria. Int. J. Curr. Res. Biosci. Plant Biol. 2015;2(4):45-49.
50. Lionberger JM, Stirewalt DL. Gene expression changes in normal haematopoietic cells. Best Practice & Research Clinical Haematology. 2009;22(2):249-269.
51. Obeagu EI, Nwosu DC. Adverse drug reactions in HIV/AIDS patients on highly active antiretro viral therapy: a review of prevalence. Int. J. Curr. Res. Chem. Pharm. Sci. 2019;6(12):45-8.DOI:  
10.22192/ijcrps.2019.06.12.004  
[links/650aba1582f01628f0335795/Adverse-drug-reactions-in-HIV-AIDS-patients-on-highly-active-antiretro-viral-therapy-a-review-of-prevalence.pdf.](#)
52. Obeagu EI, Scott GY, Amekpor F, Obeagu GU. Implications of CD4/CD8 ratios in Human Immunodeficiency Virus infections. Int. J. Curr. Res. Med. Sci. 2023;9(2):6-13.DOI:  
10.22192/ijcrms.2023.09.02.002 [links/645a4a462edb8e5f094ad37c/Implications-of-CD4-CD8-ratios-in-Human-Immunodeficiency-Virus-infections.pdf.](#)
53. Obeagu EI, Ochei KC, Okeke EI, Anode AC. Assessment of the level of haemoglobin and erythropoietin in persons living with HIV in Umuahia. Int. J. Curr. Res. Med. Sci. 2016;2(4):29-33. [links/5711c47508aebe07c02496b/Assessment-of-the-level-of-haemoglobin-and-erythropoietin-in-persons-living-with-HIV-in-Umuahia.pdf.](#)
54. Ifeanyi OE, Obeagu GU. The Values of CD4 Count, among HIV Positive Patients in FMC Owerri. Int. J. Curr. Microbiol. App. Sci. 2015;4(4):906-910.  
[https://www.academia.edu/download/38320134/Obeagu Emmanuel Ifeanyi and Obeagu Getrude Uzoma.EMMA2.pdf](https://www.academia.edu/download/38320134/Obeagu_Emanuel_Ifeanyi_and_Obeagu_Getrude_Uzoma.EMMA2.pdf).
55. Obeagu EI, Okeke EI, Anonde Andrew C. Evaluation of haemoglobin and iron profile study among persons living with HIV in Umuahia, Abia state, Nigeria. Int. J. Curr. Res. Biol. Med. 2016;1(2):1-5.
56. Ibeku JE, Nwokike GI, Nwosu DC, Obeagu EI. A Retrospective Study on Human Immune Deficiency Virus among Pregnant Women Attending Antenatal Clinic in Imo State University Teaching Hospital. *International Journal of Medical Science and Dental Research*, 2018; 1 (2):08-14.  
<https://www.ijmsdr.org/published%20paper/li1i2/A%20Retrospective%20Study%20on%20Human%20Immune%20Deficiency%20Virus%20among%20Pregnant%20Women%20Attending%20Antenatal%20Clinic%20in%20Imo%20State%20University%20Teaching%20Hospital.pdf>.
57. Obeagu EI, Obarezi TN, Omeh YN, Okoro NK, Eze OB. Assessment of some haematological and biochemical parameters in HIV patients before receiving treatment in Aba, Abia State, Nigeria. Res J Pharma Biol Chem Sci. 2014; 5:825-830.
58. Obeagu EI, Obarezi TN, Ogbuabor BN, Anaebio QB, Eze GC. Pattern of total white blood cell and differential count values in HIV positive patients receiving treatment in Federal

**Citation:** Obeagu EI, Onuoha EC. From Awareness to Action: Recommendations for HIV-Positive Pregnant Women. *Elite Journal of Public Health*, 2024; 2 (4): 75-93

- Teaching Hospital Abakaliki, Ebonyi State, Nigeria. *International Journal of Life Science, Biotechnology and Pharama Research*. 2014; 391:186-189.
59. Obeagu EI. A Review of Challenges and Coping Strategies Faced by HIV/AIDS Discordant Couples. *Madonna University journal of Medicine and Health Sciences*. 2023; 3 (1): 7-12.
60. Oloro OH, Obeagu EI. A Systematic Review on Some Coagulation Profile in HIV Infection. *International Journal of Innovative and Applied Research*. 2022;10(5):1-11.
61. Alvarez F, Fritz JH, Piccirillo CA. Pleiotropic effects of IL-33 on CD4+ T cell differentiation and effector functions. *Frontiers in immunology*. 2019; 10:438556.
62. Chirumbolo S, Bjørklund G, Sboarina A, Vella A. The role of basophils as innate immune regulatory cells in allergy and immunotherapy. *Human vaccines & immunotherapeutics*. 2018;14(4):815-831.
63. Nwosu DC, Obeagu EI, Nkwuocha BC, Nwanna CA, Nwanjo HU, Amadike JN, Ezemma MC, Okpomeshine EA, Ozims SJ, Agu GC. Alterations in superoxide dismutase, vitamins C and E in HIV infected children in Umuahia, Abia state. *International Journal of Advanced Research in Biological Sciences*. 2015;2(11):268-271.
64. Ifeanyi OE, Uzoma OG, Stella EI, Chinedum OK, Abum SC. Vitamin D and insulin resistance in HIV sero positive individuals in Umudike. *Int. J. Curr. Res. Med. Sci*. 2018;4(2):104-108.
65. Ifeanyi OE, Leticia OI, Nwosu D, Chinedum OK. A Review on blood borne viral infections: universal precautions. *Int. J. Adv. Res. Biol. Sci*. 2018;5(6):60-66.
66. Nwovu AI, Ifeanyi OE, Uzoma OG, Nwebonyi NS. Occurrence of Some Blood Borne Viral Infection and Adherence to Universal Precautions among Laboratory Staff in Federal Teaching Hospital Abakaliki Ebonyi State. *Arch Blood Transfus Disord*. 2018;1(2).
67. Chinedu K, Takim AE, Obeagu EI, Chinazor UD, Eloghosa O, Ojong OE, Odunze U. HIV and TB co-infection among patients who used Directly Observed Treatment Short-course centres in Yenagoa, Nigeria. *IOSR J Pharm Biol Sci*. 2017;12(4):70-75.
68. Offie DC, Obeagu EI, Akueshi C, Njab JE, Ekanem EE, Dike PN, Oguh DN. Facilitators and barriers to retention in HIV care among HIV infected MSM attending Community Health Center Yaba, Lagos Nigeria. *Journal of Pharmaceutical Research International*. 2021;33(52B):10-19.
69. Obeagu EI, Obeagu GU, Ede MO, Odo EO, Buhari HA. Translation of HIV/AIDS knowledge into behavior change among secondary school adolescents in Uganda: A review. *Medicine (Baltimore)*. 2023;102(49): e36599. doi: 10.1097/MD.00000000000036599. PMID: 38065920; PMCID: PMC10713174.
70. Anyiam AF, Arinze-Anyiam OC, Ironi EA, Obeagu EI. Distribution of ABO and rhesus blood grouping with HIV infection among blood donors in Ekiti State Nigeria. *Medicine (Baltimore)*. 2023;102(47): e36342. doi: 10.1097/MD.00000000000036342. PMID: 38013335; PMCID: PMC10681551.
71. Echefu SN, Udosen JE, Akwiwu EC, Akpotuzor JO, Obeagu EI. Effect of Dolutegravir regimen against other regimens on some hematological parameters, CD4 count and viral load of people living with HIV infection in South Eastern Nigeria. *Medicine (Baltimore)*. 2023;102(47): e35910. doi: 10.1097/MD.00000000000035910. PMID: 38013350; PMCID: PMC10681510.

72. Opeyemi AA, Obeagu EI. Regulations of malaria in children with human immunodeficiency virus infection: A review. *Medicine (Baltimore)*. 2023;102(46): e36166. doi: 10.1097/MD.00000000000036166. PMID: 37986340; PMCID: PMC10659731.
73. Obeagu EI, Obeagu GU, Obiezu J, Ezeonwumelu C, Ogunnaya FU, Ngwoke AO, Emeka-Obi OR,
74. Obeagu EI, Ubosi NI, Uzoma G. Storms and Struggles: Managing HIV Amid Natural Disasters. *Int. J. Curr. Res. Chem. Pharm. Sci.* 2023;10(11):14-25.
75. Obeagu EI, Obeagu GU. Human Immunodeficiency Virus and tuberculosis infection: A review of prevalence of associated factors. *Int. J. Adv. Multidiscip. Res.* 2023;10(10):56-62.
76. Obeagu EI, Obeagu GU. Unmasking the Truth: Addressing Stigma in the Fight Against HIV. *Elite Journal of Public Health*. 2024;2(1):8-22.
77. Obeagu EI, Obeagu GU, Okwuanaso CB. Optimizing Immune Health in HIV Patients through Nutrition: A Review. *Elite Journal of Immunology*. 2024;2(1):14-33.
78. Obeagu EI, Obeagu GU. Utilization of immunological ratios in HIV: Implications for monitoring and therapeutic strategies. *Medicine*. 2024;103(9): e37354.
79. Obeagu EI, Obeagu GU. CD8 Dynamics in HIV Infection: A Synoptic Review. *Elite Journal of Immunology*. 2024;2(1):1-3.
80. Obeagu EI, Obeagu GU. Implications of B Lymphocyte Dysfunction in HIV/AIDS. *Elite Journal of Immunology*. 2024;2(1):34-46.
81. Obeagu EI, Obeagu GU. Maternal Influence on Infant Immunological Responses to HIV: A Review. *Elite Journal of Laboratory Medicine*. 2024;2(1):46-58.
82. Obeagu EI, Obeagu GU. Understanding B Lymphocyte Functions in HIV Infection: Implications for Immune Dysfunction and Therapeutic Strategies. *Elite Journal of Medicine*. 2024;2(1):35-46.
83. Obeagu EI, Obeagu GU. Platelet-Driven Modulation of HIV: Unraveling Interactions and Implications. *Journal home page: <http://www.journalijar.com>*;12(01).
84. Obeagu EI, Anyiam AF, Obeagu GU. Managing Hematological Complications in HIV: Erythropoietin Considerations. *Elite Journal of HIV*. 2024;2(1):65-78.
85. Obeagu EI, Obeagu GU, Hauwa BA, Umar AI. Hematocrit Variations in HIV Patients Co-infected with Malaria: A Comprehensive Review. *Journal home page: <http://www.journalijar.com>*;12(01).
86. ObeaguEI AA, Obeagu GU. Synergistic Effects of Blood Transfusion and HIV in Children Under 5 Years with Severe Malaria: A Review. *Elite Journal of HIV*. 2024;2(1):31-50.
87. Obeagu EI, Anyiam AF, Obeagu GU. Unveiling B Cell Mediated Immunity in HIV Infection: Insights, Challenges, and Potential Therapeutic Avenues. *Elite Journal of HIV*. 2024;2(1):1-5.
88. Obeagu EI, Obeagu GU. Hematocrit Fluctuations in HIV Patients Co-infected with Malaria Parasites: A Comprehensive Review. *Int. J. Curr. Res. Med. Sci.* 2024;10(1):25-36.
89. Obeagu EI, Obeagu GU. Transfusion Therapy in HIV: Risk Mitigation and Benefits for Improved Patient Outcomes. *Sciences*. 2024;4(1):32-7.
90. Obeagu EI, Obeagu GU. Mental Health and Psychosocial Effects of natural disaster on HIV Patients. *Sciences*. 2024;4(1):38-44.

**Citation:** Obeagu EI, Onuoha EC. From Awareness to Action: Recommendations for HIV-Positive Pregnant Women. *Elite Journal of Public Health*, 2024; 2 (4): 75-93

91. Obeagu EI, Obeagu GU. Eosinophil-Associated Changes in Neonatal Thymic T Regulatory Cell Populations in HIV-Infected Pregnancies. *Elite Journal of Health Science*. 2024;2(1):33-42.
92. Obeagu EI, Obeagu GU. Advances in Understanding the Impact of Blood Transfusion on Anemia Resolution in HIV-Positive Children with Severe Malaria: A Comprehensive Review. *Elite Journal of Haematology*. 2024;2(1):26-41.
93. Obeagu EI, Ayogu EE, Obeagu GU. Interactions between Blood Transfusion and Antiretroviral Medications: Implications for Patient Care. *Elite Journal of Medicine*. 2024;2(2):104-15.
94. Obeagu EI, Obeagu GU. Maternal Eosinophilic Responses in HIV-Positive Pregnant Women: Unraveling Immunological Dynamics for Improved Maternal-Fetal Health. *Elite Journal of Immunology*. 2024;2(1):47-64.
95. Obeagu EI, Anyanwu CN, Obeagu GU. Challenges and Considerations in Managing Blood Transfusion for Individuals with HIV. *Elite Journal of HIV*. 2024;2(2):1-7.
96. Obeagu EI, Ubosi NI, Obeagu GU, Akram M. Early Infant Diagnosis: Key to Breaking the Chain of HIV Transmission. *Elite Journal of Public Health*. 2024;2(1):52-61.
97. Obeagu EI, Obeagu GU. Understanding Hematocrit Fluctuations in HIV-Malaria Coinfection for Improved Management. *Elite Journal of Public Health*. 2024;2(1):22-34.
98. Obeagu EI, Obeagu GU. The Impact of Erythropoietin on Preeclampsia in HIV-Positive Women: A Review. *Elite Journal of Nursing and Health Science*. 2024;2(1):21-31.
99. Obeagu EI, Obeagu GU. Platelet Distribution Width (PDW) as a Prognostic Marker for Anemia Severity in HIV Patients: A Comprehensive Review. *Journal home page*: [http://www.journalijar.com](http://www.journalijar.com;);12(01).
100. Obeagu EI, Obeagu GU. Neonatal Outcomes in Children Born to Mothers with Severe Malaria, HIV, and Transfusion History: A Review. *Elite Journal of Nursing and Health Science*. 2024;2(3):38-58.
101. Obeagu EI, Obeagu GU. Assessing Platelet Functionality in HIV Patients Receiving Antiretroviral Therapy: Implications for Risk Assessment. *Elite Journal of HIV*. 2024;2(3):14-26.
102. Obeagu EI, Obeagu GU. Advancements in HIV Prevention: Africa's Trailblazing Initiatives and Breakthroughs. *Elite Journal of Public Health*. 2024;2(1):52-63.
103. Obeagu EI, Obeagu GU. Maternal Influence on Infant Immunological Responses to HIV: A Review. *Elite Journal of Laboratory Medicine*. 2024;2(1):46-58.
104. Obeagu EI, Obeagu GU. Counting Cells, Shaping Fates: CD4/CD8 Ratios in HIV. *Elite Journal of Scientific Research and Review*. 2024;2(1):37-50.
105. Obeagu EI, Anyiam AF, Obeagu GU. Managing Hematological Complications in HIV: Erythropoietin Considerations. *Elite Journal of HIV*. 2024;2(1):65-78.
106. Obeagu EI, Obeagu GU. Immune Modulation in HIV-Positive Neonates: Insights and Implications for Clinical Management. *Elite Journal of Nursing and Health Science*. 2024;2(3):59-72.
107. Obeagu EI, Ayogu EE, Obeagu GU. Impact on Viral Load Dynamics: Understanding the Interplay between Blood Transfusion and Antiretroviral Therapy in HIV Management. *Elite Journal of Nursing and Health Science*. 2024;2(2):5-15.

**Citation:** Obeagu EI, Onuoha EC. From Awareness to Action: Recommendations for HIV-Positive Pregnant Women. *Elite Journal of Public Health*, 2024; 2 (4): 75-93



108. Obeagu EI, Obeagu GU. Understanding B Lymphocyte Functions in HIV Infection: Implications for Immune Dysfunction and Therapeutic Strategies. *Elite Journal of Medicine*. 2024;2(1):35-46.
109. Obeagu EI, Anyanwu CN, Obeagu GU. Challenges and Considerations in Managing Blood Transfusion for Individuals with HIV. *Elite Journal of HIV*. 2024;2(2):1-7.
110. Obeagu EI, Obeagu GU. Understanding ART and Platelet Functionality: Implications for HIV Patients. *Elite Journal of HIV*. 2024;2(2):60-73.
111. Obeagu EI, Obeagu GU. The Role of Blood Transfusion Strategies in HIV Management: Current Insights and Future Directions. *Elite Journal of Medicine*. 2024;2(1):10-22.
112. Obeagu EI, AmaezeAA O, Obeagu GU. B Cell Deficiency and Implications in HIV Pathogenesis: Unraveling the Complex Interplay. *Elite Journal of Nursing and Health Science*. 2024;2(2):33-46.
113. Obeagu EI, Obeagu GU. Eosinophil Dynamics in Pregnancy among Women Living with HIV: A Comprehensive Review. *Int. J. Curr. Res. Med. Sci*. 2024;10(1):11-24.
114. Obeagu EI, Obeagu GU. Hematocrit Fluctuations in HIV Patients Co-infected with Malaria Parasites: A Comprehensive Review. *Int. J. Curr. Res. Med. Sci*. 2024;10(1):25-36.
115. Obeagu EI, Obeagu GU. Unveiling the Role of Innate Immune Activation in Pediatric HIV: A Review. *Elite Journal of Immunology*. 2024;2(3):33-44.
116. Obeagu EI, Obeagu GU. Harnessing B Cell Responses for Personalized Approaches in HIV Management. *Elite Journal of Immunology*. 2024;2(2):15-28.
117. Obeagu EI, Obeagu GU, Hauwa BA, Umar AI. Neutrophil Dynamics: Unveiling Their Role in HIV Progression within Malaria Patients. *Journal home page: <http://www.journalijar.com>*;12(01).
118. Obeagu EI, Obeagu GU, Hauwa BA, Umar AI. Hematocrit Variations in HIV Patients Co-infected with Malaria: A Comprehensive Review. *Journal home page: <http://www.journalijar.com>*;12(01).
119. Obeagu EI, Igwe MC, Obeagu GU. The Power of Unity: Collective Efforts in Confronting HIV Stigma. *Elite Journal of Public Health*. 2024;2(3):22-36.
120. Obeagu EI, Anyiam AF, Obeagu GU. Managing Anemia in HIV through Blood Transfusions: Clinical Considerations and Innovations. *Elite Journal of HIV*. 2024;2(1):16-30.
121. Obeagu EI, Obeagu GU. Maternal Eosinophilic Responses in HIV-Positive Pregnant Women: Unraveling Immunological Dynamics for Improved Maternal-Fetal Health. *Elite Journal of Immunology*. 2024;2(1):47-64.
122. Obeagu EI, Obeagu GU. Platelet Aberrations in HIV Patients: Assessing Impacts of ART. *Elite Journal of Haematology*, 2024; 2 (3):10-24.
123. Obeagu EI, Obeagu GU. Hematological Changes Following Blood Transfusion in Young Children with Severe Malaria and HIV: A Critical Review. *Elite Journal of Laboratory Medicine*. 2024;2(1):33-45.
124. Obeagu EI, Anyiam AF, Obeagu GU. Erythropoietin Therapy in HIV-Infected Individuals: A Critical Review. *Elite Journal of HIV*. 2024;2(1):51-64.

**Citation:** Obeagu EI, Onuoha EC. From Awareness to Action: Recommendations for HIV-Positive Pregnant Women. *Elite Journal of Public Health*, 2024; 2 (4): 75-93

125. Obeagu EI, Ubosi NI, Obeagu GU, Obeagu AA. Nutritional Strategies for Enhancing Immune Resilience in HIV: A Review. *Int. J. Curr. Res. Chem. Pharm. Sci.* 2024;11(2):41-51.
126. Obeagu EI, Obeagu GU. The Crucial Role of Erythropoietin in Managing Anemia in HIV: A Review. *Elite Journal of Scientific Research and Review.* 2024;2(1):24-36.
127. Obeagu EI, Obeagu GU. Impact of Maternal Eosinophils on Neonatal Immunity in HIV-Exposed Infants: A Review. *Elite Journal of Immunology.* 2024;2(3):1-8.
128. Obeagu EI, Anyiam AF, Obeagu GU. Unveiling B Cell Mediated Immunity in HIV Infection: Insights, Challenges, and Potential Therapeutic Avenues. *Elite Journal of HIV.* 2024;2(1):1-5.
129. Obeagu EI, Obeagu GU. Anemia and Erythropoietin: Key Players in HIV Disease Progression. *Elite Journal of Haematology,* 2024; 2 (3):.42-57.
130. Obeagu EI, Obeagu GU. Platelet Dysfunction in HIV Patients: Assessing ART Risks. *Elite Journal of Scientific Research and Review.* 2024;2(1):1-6.
131. Obeagu EI, Ubosi NI, Obeagu GU, Akram M. Early Infant Diagnosis: Key to Breaking the Chain of HIV Transmission. *Elite Journal of Public Health.* 2024;2(1):52-61.
132. Obeagu EI, Obeagu GU. Transfusion Therapy in HIV: Risk Mitigation and Benefits for Improved Patient Outcomes. *Sciences.* 2024;4(1):32-7.
133. Obeagu EI, Obeagu GU. P-Selectin and Immune Activation in HIV: Clinical Implications. *Elite Journal of Health Science.* 2024;2(2):16-29.
134. Obeagu EI, Obeagu GU. Mental Health and Psychosocial Effects of natural disaster on HIV Patients. *Sciences.* 2024;4(1):38-44.
135. Obeagu EI, Obeagu GU. Optimizing Blood Transfusion Protocols for Breast Cancer Patients Living with HIV: A Comprehensive Review. *Elite Journal of Nursing and Health Science.* 2024;2(2):1-7.
136. Obeagu EI, Obeagu GU. Advances in Understanding the Impact of Blood Transfusion on Anemia Resolution in HIV-Positive Children with Severe Malaria: A Comprehensive Review. *Elite Journal of Haematology.* 2024;2(1):26-41.
137. Obeagu EI, Obeagu GU. Transfusion-Related Complications in Children Under 5 with Coexisting HIV and Severe Malaria: A Review. *Int. J. Curr. Res. Chem. Pharm. Sci.* 2024;11(2):9-19.
138. Obeagu EI, Obeagu GU. Impact of Blood Transfusion on Viral Load Dynamics in HIV-Positive Neonates with Severe Malaria: A Review. *Elite Journal of Scientific Research and Review.* 2024;2(1):42-60.
139. Obeagu EI, Ayogu EE, Obeagu GU. Interactions between Blood Transfusion and Antiretroviral Medications: Implications for Patient Care. *Elite Journal of Medicine.* 2024;2(2):104-5.
140. Obeagu EI, Obeagu GU, Odo EO, Igwe MC, Ugwu OP, Alum EU, Racheal P. Combatting Stigma: Essential Steps in Halting HIV Spread. *IAA Journal of Applied Sciences.* 2024;11(1):22-9.
141. Obeagu EI, Obeagu GU. P-Selectin Expression in HIV-Associated Coagulopathy: Implications for Treatment. *Elite Journal of Haematology,* 2024; 2 (3):.25-41.

142. Obeagu EI, Obeagu GU. Eosinophil-Associated Changes in Neonatal Thymic T Regulatory Cell Populations in HIV-Infected Pregnancies. *Elite Journal of Health Science*. 2024;2(1):33-42.
143. Obeagu EI, Obeagu GU. Exploring the Role of L-selectin in HIV-related Immune Exhaustion: Insights and Therapeutic Implications. *Elite Journal of HIV*. 2024;2(2):43-59.
144. Obeagu EI. Erythropoietin and the Immune System: Relevance in HIV Management. *Elite Journal of Health Science*. 2024;2(3):23-35.
145. Obeagu EI, Obeagu GU. The Impact of Erythropoietin on Preeclampsia in HIV-Positive Women: A Review. *Elite Journal of Nursing and Health Science*. 2024;2(1):21-31.
146. Obeagu EI, Obeagu GU. Unraveling the Role of Eosinophil Extracellular Traps (EETs) in HIV-Infected Pregnant Women: A Review. *Elite Journal of Nursing and Health Science*. 2024;2(3):84-99.
147. Obeagu EI, Obeagu GU. Hematologic Considerations in Breast Cancer Patients with HIV: Insights into Blood Transfusion Strategies. *Elite Journal of Health Science*. 2024;2(2):20-35.
148. Obeagu EI, Obeagu GU. L-selectin and HIV-Induced Immune Cell Trafficking: Implications for Pathogenesis and Therapeutic Strategies. *Elite Journal of Laboratory Medicine*. 2024;2(2):30-46.
149. Obeagu EI, Obeagu GU. The Intricate Relationship Between Erythropoietin and HIV-Induced Anemia: Unraveling Pathways for Therapeutic Insights. *Int. J. Curr. Res. Chem. Pharm. Sci*. 2024;11(2):30-40.
150. Obeagu EI, Obeagu GU. The Role of L-selectin in Tuberculosis and HIV Coinfection: Implications for Disease Diagnosis and Management. *Elite Journal of Public Health*. 2024;2(1):35-51.
151. Kalu OA, Ukibe NR, Onyenekwe CC, Okoyeagu RC, Nnaemeka WS, Onyenekwe AJ, Ukibe EG, Ukibe BC, Ukibe VE, Obeagu EI. Assessment of Serum Cystatin C, Microalbumin Levels and Egfr in HIV Seropositive Individuals based on Age and Gender in NAUTH, Nnewi, Nigeria. *Elite Journal of Medicine*. 2024;2(3):48-59.
152. Obeagu EI, Obeagu GU. Understanding Immune Cell Trafficking in Tuberculosis-HIV Coinfection: The Role of L-selectin Pathways. *Elite Journal of Immunology*. 2024;2(2):43-59.
153. Obeagu EI, Obeagu GU. Eosinophilic Changes in Placental Tissues of HIV-Positive Pregnant Women: A Review. *Elite Journal of Laboratory Medicine*. 2024;2(1):14-32.
154. Obeagu EI, Obeagu GU. P-Selectin and Platelet Activation in HIV: Implications for Antiviral Therapy. *Elite Journal of Scientific Research and Review*. 2024;2(1):17-41.
155. Obeagu EI, Obeagu GU. Strength in Unity: Building Support Networks for HIV Patients in Uganda. *Elite Journal of Medicine*. 2024;2(1):1-6.
156. Obeagu EI, GU EE. Understanding the Intersection of Highly Active Antiretroviral Therapy and Platelets in HIV Patients: A Review. *Elite Journal of Haematology*, 2024; 2 (3):111-7.
157. Obeagu EI, Obeagu GU. Anemia in HIV: The Role of Erythropoietin in Disease Progression. *Elite Journal of Haematology*, 2024; 2(4): 51-67

**Citation:** Obeagu EI, Onuoha EC. From Awareness to Action: Recommendations for HIV-Positive Pregnant Women. *Elite Journal of Public Health*, 2024; 2 (4): 75-93

158. Obeagu EI, Obeagu GU. **ART and Platelet Dynamics: Assessing Implications for HIV Patient Care.** *Elite Journal of Haematology*, 2024; 2(4): 68-85
159. Obeagu EI, Obeagu GU. Impact of Breastfeeding on Infant Immune Responses in the Context of HIV. *Elite Journal of Nursing and Health Science*, 2024; 2(4):23-39
160. Obeagu EI, Obeagu GU. HIV-Induced Immune Exhaustion in Neonates: A Review of Mechanisms and Implications. *Elite Journal of Immunology*, 2024; 2(3): 45-61
161. Obeagu EI, Obeagu GU. Immunodeficiency and Immune Reconstitution in Pediatric HIV: Mechanisms, Challenges, and Therapeutic Strategies. *Elite Journal of Immunology*, 2024; 2(3): 62-79
162. Obeagu EI, Obeagu GU. Hematological Consequences of Erythropoietin in HIV: Clinical Implications. *Elite Journal of Haematology*, 2024; 2(4): 86-104
163. Obeagu EI, Obeagu GU. GATA-1 and Hematopoietic Stem Cell Dysfunction in HIV-Related Hematological Malignancies: A Review. *Elite Journal of Haematology*, 2024; 2(4): 105-122
164. Obeagu EI, Obeagu GU. Exploration of Intricate Relationship between GATA-1 and Anemia in HIV. *Elite Journal of Haematology*, 2024; 2(4): 123-140
165. Obeagu EI, Obeagu GU. GATA-1 and Immune Dysregulation in HIV/AIDS: Implications for Therapy. *Elite Journal of HIV*, 2024; 2(3): 69-85
166. Obeagu EI, Obeagu GU. The Role of GATA-1 in Erythropoietin Response and Resistance in HIV/AIDS. *Elite Journal of HIV*, 2024; 2(4): 1-17
167. Obeagu EI, Obeagu GU. Understanding the Role of GATA-1 in T-Cell Development in the Context of HIV Infection. *Elite Journal of HIV*, 2024; 2(4): 18-34
168. Obeagu EI, Obeagu GU. Programmed Cell Death Protein 1 (PD-1) Pathway Modulation in HIV/AIDS: From Bench to Bedside. *Elite Journal of HIV*, 2024; 2(4): 35-53
169. Obeagu EI, Obeagu GU. Programmed Cell Death Protein 1 (PD-1) and Immune Checkpoint Inhibitors in HIV-Related Lymphomas: Current Insights and Future Directions. *Elite Journal of Immunology*, 2024; 2(4): 1-17
170. Obeagu EI, Obeagu, GU. Programmed Cell Death Protein 1 (PD-1) Signaling in HIV-Associated Cardiovascular Disease: Mechanisms and Therapeutic Implications. *Elite Journal of Scientific Research and Review*, 2024; 2(1): 61-77
171. Obeagu EI, Obeagu, GU. Cytotoxic T-Lymphocyte-Associated Protein 4 (CTLA-4) Blockade and HIV-Associated Kaposi Sarcoma: A Promising Therapeutic Strategy. *Elite Journal of Scientific Research and Review*, 2024; 2(1): 78-94
172. Obeagu EI, Obeagu GU. The Impact of Cytotoxic T-Lymphocyte-Associated Protein 4 (CTLA-4) Genetic Variations on HIV Susceptibility and Progression. *Elite Journal of Immunology*, 2024; 2(4): 18-35
173. Obeagu EI, Obeagu, GU. Antacid Use in HIV Patients: Implications for Drug Absorption, Metabolism, and Adverse Effects. *Elite Journal of Scientific Research and Review*, 2024; 2(3): 1-19
174. Obeagu EI, Obeagu GU. Erythropoietin Signaling and its Implications in HIV-Related Anemia: A Comprehensive Review. *Elite Journal of HIV*, 2024; 2(4): 54-71

175. Obeagu EI, Obeagu, GU. The Role of GATA-1 in Megakaryocyte Function and Platelet Production During HIV Infection: A Review. *Elite Journal of Scientific Research and Review*, 2024; 2(3): 20-36
176. Obeagu EI, Obeagu GU. GATA-1 and Bone Marrow Failure Syndromes in the Context of HIV Infection: A Review of Molecular Mechanisms and Therapeutic Implications. *Elite Journal of Laboratory Medicine*, 2024; 2(3): 39-56
177. Obeagu EI, Obeagu GU. GATA-1 Mutations and Their Association with HIV-Associated Hematological Disorders: A Review. *Elite Journal of Health Science*, 2024; 2(4): 7-23
178. Obeagu EI, Obeagu GU. GATA-1 and Hematopoietic Stem Cell Maintenance in HIV: Mechanisms and Implications. *Elite Journal of Health Science*, 2024; 2(4): 24-40
179. Obeagu EI, Obeagu GU. GATA-1 Regulation of Erythroid Progenitor Cell Differentiation in HIV/AIDS: Molecular Insights and Therapeutic Implications. *Elite Journal of Haematology*, 2024; 2(4): 141-159
180. Obeagu EI, Obeagu GU. Role of GATA-1 in Megakaryopoiesis and Thrombopoiesis During HIV Infection: Molecular Insights and Therapeutic Implications. *Elite Journal of Nursing and Health Science*, 2024; 2(4):40-59
181. Obeagu EI, Obeagu GU. GATA-1 as a Modulator of Immune Responses in HIV-Infected Individuals: Implications for Disease Pathogenesis and Therapeutic Interventions. *Elite Journal of Laboratory Medicine*, 2024; 2(3): 57-74
182. Obeagu EI, Obeagu GU. GATA-1 and Inflammatory Signaling Pathways in HIV-Related Hematological Disorders: Mechanisms and Therapeutic Implications. *Elite Journal of Health Science*, 2024; 2(3):27-44
183. Obeagu EI, Obeagu GU. GATA-1 and Coagulation Cascade Regulation in HIV-Associated Hematological Complications: Mechanisms and Therapeutic Implications. *Elite Journal of Health Science*, 2024; 2(3):45-63
184. Obeagu EI, Obeagu GU. GATA-1 and HIV-Associated Myelodysplastic Syndromes: Pathogenesis and Treatment Strategies. *Elite Journal of Medicine*, 2024; 2(4): 1-18
185. Obeagu EI, Obeagu GU. GATA-1 and Hematopoietic Stem Cell Quiescence in HIV: Implications for Therapy. *Elite Journal of Medicine*, 2024; 2(4): 19-36
186. Obeagu EI, Onuoha EC, Hallie EF. GATA-1 Regulation of Coagulation Pathways in HIV-Associated Deep Venous Thrombosis: Molecular Insights and Therapeutic Implications. *Elite Journal of Haematology*, 2024; 2(4): 160-179
187. Obeagu EI, Onuoha EC, Hallie EF. Impact of L-selectin on Immune Cell Trafficking in Tuberculosis and HIV Coinfection: A Review. *Elite Journal of Immunology*, 2024; 2(4): 54-72
188. Obeagu EI, Onuoha EC. L-Selectin in Tuberculosis-HIV Coinfection: Linking Immune Cell Trafficking to Disease Pathogenesis. *Elite Journal of Laboratory Medicine*, 2024; 2(4): 7-25
189. Obeagu EI, Obeagu GU. L-selectin and HIV-Induced Immune Cell Trafficking: Implications for Pathogenesis and Therapeutic Strategies. *Elite Journal of Laboratory Medicine*. 2024;2(2):30-46.



190. Obeagu EI, Obeagu GU. Exploring the Role of L-selectin in HIV-related Immune Exhaustion: Insights and Therapeutic Implications. *Elite Journal of HIV*. 2024;2(2):43-59.
191. Obeagu EI, Obeagu GU. Understanding Immune Cell Trafficking in Tuberculosis-HIV Coinfection: The Role of L-selectin Pathways. *Elite Journal of Immunology*. 2024;2(2):43-59.
192. Obeagu EI, Obeagu GU. P-Selectin and Immune Activation in HIV: Clinical Management Strategies. *Elite Journal of Immunology*. 2024;2(2):29-42.
193. Obeagu EI, Obeagu GU. The Role of L-selectin in Tuberculosis and HIV Coinfection: Implications for Disease Diagnosis and Management. *Elite Journal of Public Health*. 2024;2(1):35-51.
194. Obeagu EI, Obeagu GU. P-Selectin and Platelet Activation in HIV: Implications for Antiviral Therapy. *Elite Journal of Scientific Research and Review*. 2024;2(1):17-41.
195. Obeagu EI, Obeagu GU. P-Selectin Expression in HIV-Associated Coagulopathy: Implications for Treatment. *Elite Journal of Haematology*, 2024; 2 (3):25-41.
196. Obeagu EI, Onuoha EC. Modulation of L-selectin Expression in Tuberculosis-HIV Coinfection: Implications for Disease Control. *Elite Journal of Public Health*, 2024; 2 (4): 56-74
197. Obeagu EI, Onuoha EC. L-selectin in Tuberculosis-HIV Coinfection: Linking Immune Activation to Disease Outcome. *Elite Journal of Health Science*, 2024; 2(4): 41-58
198. Obeagu EI, Obeagu GU. Role of L-selectin in Tuberculosis-HIV Coinfection: Implications for Immune Activation and Dysfunction. *Elite Journal of HIV*, 2024; 2(4): 72-90
199. Obeagu EI, Obeagu GU. A Roadmap for Reducing HIV Transmission from Mother to Child: Strategies, Challenges, and Future Directions. *Elite Journal of HIV*, 2024; 2(4): 91-109